Q1 Earnings Estimate for Cytokinetics Issued By B. Riley

Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) - Stock analysts at B. Riley issued their Q1 2025 earnings estimates for shares of Cytokinetics in a research note issued to investors on Wednesday, March 5th. B. Riley analyst M. Mamtani expects that the biopharmaceutical company will earn ($1.46) per share for the quarter. The consensus estimate for Cytokinetics' current full-year earnings is ($5.24) per share. B. Riley also issued estimates for Cytokinetics' Q2 2025 earnings at ($1.40) EPS, Q3 2025 earnings at ($1.44) EPS, Q4 2025 earnings at ($1.34) EPS and FY2029 earnings at $1.06 EPS.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, topping the consensus estimate of ($1.29) by $0.03. The business had revenue of $16.93 million during the quarter, compared to the consensus estimate of $14.26 million.

A number of other analysts have also weighed in on the stock. Mizuho increased their target price on shares of Cytokinetics from $99.00 to $103.00 and gave the stock an "outperform" rating in a report on Thursday, November 21st. Stifel Nicolaus started coverage on shares of Cytokinetics in a research report on Wednesday, January 22nd. They set a "buy" rating and a $80.00 price target on the stock. HC Wainwright reaffirmed a "buy" rating and set a $120.00 price objective on shares of Cytokinetics in a research report on Friday, February 28th. Royal Bank of Canada increased their target price on Cytokinetics from $80.00 to $82.00 and gave the stock an "outperform" rating in a research report on Wednesday, December 18th. Finally, JMP Securities restated a "market outperform" rating and set a $78.00 price target on shares of Cytokinetics in a research report on Friday, February 7th. Two equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $82.00.

Remove Ads

Cytokinetics Trading Down 0.3 %

CYTK traded down $0.12 on Thursday, hitting $43.31. 1,674,630 shares of the company were exchanged, compared to its average volume of 1,574,128. The stock has a market capitalization of $5.13 billion, a PE ratio of -8.05 and a beta of 0.95. Cytokinetics has a 12 month low of $40.53 and a 12 month high of $75.71. The company has a debt-to-equity ratio of 5.93, a quick ratio of 9.28 and a current ratio of 9.28. The firm has a fifty day simple moving average of $46.65 and a two-hundred day simple moving average of $50.66.

Insider Activity at Cytokinetics

In other Cytokinetics news, Director John T. Henderson sold 1,780 shares of the company's stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $50.42, for a total transaction of $89,747.60. Following the transaction, the director now owns 38,461 shares in the company, valued at approximately $1,939,203.62. This represents a 4.42 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Fady Ibraham Malik sold 7,300 shares of Cytokinetics stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $50.64, for a total transaction of $369,672.00. Following the completion of the sale, the executive vice president now owns 116,071 shares of the company's stock, valued at $5,877,835.44. This represents a 5.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 38,133 shares of company stock valued at $1,755,790. 3.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Cytokinetics

Several institutional investors and hedge funds have recently added to or reduced their stakes in CYTK. International Assets Investment Management LLC bought a new position in shares of Cytokinetics during the 3rd quarter valued at $558,000. State of Alaska Department of Revenue grew its stake in shares of Cytokinetics by 7.4% during the 3rd quarter. State of Alaska Department of Revenue now owns 13,390 shares of the biopharmaceutical company's stock valued at $706,000 after purchasing an additional 925 shares during the period. New York State Teachers Retirement System increased its position in shares of Cytokinetics by 1.4% during the 3rd quarter. New York State Teachers Retirement System now owns 113,800 shares of the biopharmaceutical company's stock valued at $6,009,000 after purchasing an additional 1,600 shares during the last quarter. Van ECK Associates Corp lifted its stake in shares of Cytokinetics by 21.3% in the 3rd quarter. Van ECK Associates Corp now owns 71,691 shares of the biopharmaceutical company's stock worth $3,802,000 after purchasing an additional 12,565 shares during the period. Finally, Crossmark Global Holdings Inc. boosted its holdings in shares of Cytokinetics by 16.3% in the third quarter. Crossmark Global Holdings Inc. now owns 7,640 shares of the biopharmaceutical company's stock worth $403,000 after buying an additional 1,072 shares during the last quarter.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.